Initiation of take-home methadone dosing within 5 to 24 weeks after OAT induction significantly reduces all-cause mortality and methadone discontinuation compared to no take-home dosing.
Any initiation of take-home dosing, even as early as within 4 weeks, is associated with better outcomes than daily witnessed ingestion without take-home privileges.
COVID-19 pandemic-related regulatory relaxations enhancing take-home dosing led to improved treatment retention and increased enrollment without adversely affecting survival.
Urine drug testing frequency and baseline polysubstance use impact treatment retention, but baseline anxiety does not significantly affect OAT retention, highlighting multifactorial determinants of treatment success.
